Results 101 to 110 of about 5,184 (154)

Real-world untreated risk of hospitalization and death in a nirmatrelvir/ritonavir treatment-eligible population with mild-to-moderate COVID-19 in the United States: a systematic literature review. [PDF]

BMC Infect Dis
Migliaccio-Walle K, Mugwagwa T, Cha-Silva AS, Gong CL, Campbell D, Quercia R, Bergroth T, Veenstra DL, Moran MM, Dzingina M.   +9 more
europepmc   +1 more source

Effectiveness and safety of azvudine versus nirmatrelvir/ritonavir in hospitalized patients with COVID-19. [PDF]

BMC Infect Dis
Yang J, Min J, Ding L, Liu R, Yang Y, Zhang JF, Lei W.   +6 more
europepmc   +1 more source

Real-World Effectiveness of Nirmatrelvir-Ritonavir Against Severe Outcomes of COVID-19 in Taiwan: A Nationwide Population-Based Cohort Study. [PDF]

Open Forum Infect Dis
Kuo RN, Chen W, Shau WY, Chang SC.
europepmc   +1 more source

Safety and Effectiveness of Nirmatrelvir-Ritonavir in Patients With Advanced Kidney Dysfunction and COVID-19. [PDF]

Am J Kidney Dis
Contreras Nieves M, Anand S, Thomas IC, Geldsetzer P, Fung E, Tamura MK, Montez-Rath ME.   +6 more
europepmc   +1 more source

Plasma concentration of voriconazole under concomitant use of nirmatrelvir/ritonavir in patients with COVID-19: a multicenter retrospective study. [PDF]

Front Pharmacol
Shi H, Zhang X, Kong Q, Yu L, Yu Z.
europepmc   +1 more source

Molnupiravir in Combination With Nirmatrelvir/Ritonavir: No Cause for Alarm. [PDF]

J Infect Dis
Kuritzkes DR.
europepmc   +1 more source

Optimized tacrolimus dosing strategy in kidney transplant recipients receiving nirmatrelvir-ritonavir for COVID-19. [PDF]

PLoS One
Yan H, Hu S, Zhang H, Zhou Y, Fu R, Xu P, Cai H, Li X, Lan G.   +8 more
europepmc   +1 more source

The Impact of COVID-19 and the Practical Importance of Vaccinations and Nirmatrelvir/Ritonavir for Patients with Cardiovascular Disease. [PDF]

Vaccines (Basel)
Wełnicki M, Mamcarz A, Kuchar E, Mitkowski P, Jaroszewicz J, Tomasiewicz K, Gąsior M, Leszek P, Kamiński KA, Wysocki J.   +9 more
europepmc   +1 more source